You just read:

Telik Announces Preliminary Agreement On Design Of Phase 3 Registration Trial Of Telintra® In Low To Intermediate-1 Risk Myelodysplastic Syndrome

News provided by

Telik, Inc.

Jan 22, 2013, 05:30 EST